AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Cogent Biosciences Inc. (COGT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

8.10

0.02 (0.25%)

At close: Feb 20, 2025, 3:59 PM

8.07

-0.31%

After-hours: Feb 20, 2025, 04:56 PM EST

undefined% (undefined)

Bid	7.5
Market Cap	894.19M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.48
PE Ratio (ttm)	-3.26
Forward PE	n/a
Analyst	Hold

Ask	8.15
Volume	483,542
Avg. Volume (20D)	1,533,572
Open	8.14
Previous Close	8.08
Day's Range	7.88 - 8.10
52-Week Range	5.73 - 12.61
Beta	undefined

About COGT

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 29, 2018

Employees 164

Stock Exchange NASDAQ

Ticker Symbol COGT

Website https://www.cogentbio.com

Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for COGT stock is "Hold." The 12-month stock price forecast is $14.5, which is an increase of 79.12% from the latest price.

Buy 50.00%

Hold 50.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

3 months ago

-15.84%

Cogent Biosciences shares are trading lower after ... Unlock content with Pro Subscription

8 months ago

-6.12%

Cogent Biosciences shares are trading lower. The company announced additional data from Part 1 of its ongoing SUMMIT clinical trial evaluating the selective KIT D816V inhibitor, bezuclastinib, in patients with nonadvanced systemic mastocytosis.

News

1 week ago · zacks.com

Is Cogent Biosciences (COGT) Outperforming Other Medical Stocks This Year?

Here is how Cogent Biosciences, Inc. (COGT) and Cardiol Therapeutics Inc. (CRDL) have performed compared to their sector so far this year.

1 month ago · seekingalpha.com

3 Biotech Stocks With Notable Insider Buying

Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-ca...

1 month ago · seekingalpha.com

Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data

Bezuclastinib is COGT's main value driver, currently undergoing 3 late-stage trials for SM and GIST. COGT's SUMMIT Part 2 for nonAdvSM will give us decisive data in July 2025, which I consider its mai...

2 months ago · benzinga.com

Why Is Cogent Biosciences Stock Trading Higher On Monday?

On Sunday, Cogent Biosciences, Inc. COGT revealed updated clinical results from the Open Label Extension (OLE) portion of the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mast...